Xsulin 30/70 Suspension for Injection

Xsulin 30/70 is administered via subcutaneous injection, with dosage individualized based on patient-specific factors including blood glucose monitoring results, dietary intake, and physical activity. It is essential to rotate injection sites to minimize lipodystrophy. This insulin suspension should not be administered intravenously or intramuscularly. Patients must be educated on recognizing and managing hypoglycemia, a potential adverse effect associated with insulin therapy.

Proper storage at 2–8°C is required to maintain potency, avoiding freezing or exposure to direct heat or light. Xsulin 30/70 may be used alone or in combination with other antidiabetic agents under medical supervision. Regular monitoring of blood glucose and periodic assessment of HbA1c levels are recommended to optimize therapeutic outcomes and reduce the risk of diabetes-related complications.